Tweak and FN14 in central nervous system health and disease

Frontiers in Bioscience

Volumn 12, Issue 8, 2007, Pages 2772-2781

  Yepes, Manuel ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain barrier; Fn14; MS; Multiple sclerosis; Neurovascular Unit; Review; Stroke; TNF; Tumor; TWEAK

Indexed keywords

TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTORS;

EID: 34347216709     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2271     Document Type: Review

References (70)

1. C. F. Ware: The TNF superfamily. Cytokine Growth Factor Rev 14, 181-184 (2003)
2. A. E. Juedes, P. Hjelmstrom, C. M. Bergman, A. L. Neild, and N. H. Ruddle: Kinetics and cellular origin of cytokines in the central nervous system: insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J. Immunol 164, 419-426 (2000) (Pubitemid 30013017)
3. G. Z. Feuerstein, X. Wang and F. C. Barone: Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets. Ann. N. Y. Acad. Sci 825, 179-93 (1997) (Pubitemid 27503715)
4. Y. Chicheportiche, P. R. Bourdon, H. Xu, Y. M. Hsu, H. Scott, C. Hession, L. Garcia, and J. L. Browning: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem 272, 32401-32410 (1997) (Pubitemid 28011923)
5. R. L. Meighan-Mantha, D. K. Hsu, Y. Guo, S. A. Brown, S. L. Feng, S. L, K. A. Peifley, G. F. Alberts, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, C. M. Richards, and J. A. Winkles: The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J. Biol. Chem 274, 33166-33176 (1999) (Pubitemid 129535361)
6. S. L. Feng, Y. Guo, V. M. Factor, S. S. Thorgeirsson, D. W. Bell, J. R. Testa, K. A. Peifley, and J. A. Winkles: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am. J. Pathol 156, 1253-1261 (2000) (Pubitemid 30660004)
7. S. R. Wiley, L. Cassiano, T. Lofton, T. Davis-Smith, J. A. Winkles, V. Lindner, H. Liu, T. O. Daniel, C. A. Smith, and W. C. Fanslow: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15, 837-846 (2001) (Pubitemid 34008510)
8. M. Yepes, S. A. Brown, E. G. Moore, E. P. Smith, D. A. Lawrence, and JA Winkles: A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am. J. Pathol 166, 511-520 (2005) (Pubitemid 40189047)
9. S. Desplat-Jego, S. Varriale, R. Creidy, R. Terra, D. Bernard, M. Khrestchatisky, S. Izui, Y. Chicheportiche and J. Boucraut: TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J. Neuroimmunol 133, 116-123 (2002) (Pubitemid 35346733)
10. S. R. Wiley and J. A. Winkles: TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 14, 241-249 (2003) (Pubitemid 36693144)
11. T. Kawakita, K. Shiraki, Y. Yamanaka, Y. Yamaguchi, Y. Saitou, N. Enokimura, N. Yamamoto, H. Okano, K. Sugimoto, K. Murata and T. Nakano: Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem. Biophys. Res. Commun 318, 726-733 (2004) (Pubitemid 38624215)
12. S. H. Kim, Y. J. Kang, W. J. Kim, D. K. Woo, Y. Lee, Y., D. I. Kim, Y. B. Park, B. S. Kwon, J. E. Park and W. H. Lee: TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ. J 68, 396-399 (2004) (Pubitemid 38470720)
13. T. Kawakita, K. Shiraki, Y Yamanaka, Y. Yamaguchi, Y. Saitou, N. Enokimura, N. Yamamoto, H. Okano, K. Sugimoto, K. Murata and T. Nakano: Functional expression of TWEAK in human colonic adenocarcinoma cells. Int. J. Oncol 26, 87-93 (2005)
14. H. Maecker, E. Varfolomeev, F. Kischkel, D. Lawrence, H. LeBlanc, W. Lee, S. Hurst, D. Danilenko, J. Li, E. Filvaroff, B. Yang, D. Daniel and A. Ashkenazi: TWEAK attenuates the transition from innate to adaptive immunity. Cell 123, 931-944 (2005) (Pubitemid 41721037)
15. N. Felli, F. Pedini, A. Zeuner, E. Petrucci, T. Testa, C. Conticello, M. Biffoni, C. A. Di, J. A. Winkles, C. Peschle and M. R. De: Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J. Immunol 175, 1464-1472 (2005) (Pubitemid 41023046)
16. M. R. Chacon, C. Richart, J. M. Gomez, A. Megia, N. Vilarrasa, J. M. Fernandez-Real, A. Garcia-Espana, M. Miranda, C. Masdevall, W. Ricard, E. Caubet, J Soler and J. Vendrell: Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine 33, 129-137 (2006)
17. S. A. Marsters, J. P. Sheridan, R. M. Pitti, J. Brush, A. Goddard and A. Ashkenazi: Identification of a ligand for the death-domain-containing receptor Apo3. Curr. Biol 8, 525-528 (1998) (Pubitemid 28203072)
18. B. Pradet-Balade, J. P. Medema, M. Lopez-Fraga, J. C. Lozano, G. M. Kolfschoten, A. Picard, A. Martinez, J. A. Garcia-Sanz and M. Hahne: An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J 21, 5711-5720 (2002) (Pubitemid 35315271)
19. K. Tanabe, I. Bonilla, J. A. Winkles and S. M. Strittmatter: Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth. J. Neurosci 23, 9675-9686 (2003) (Pubitemid 37352067)
20. I. Potrovita, W. Zhang, L. Burkly, K. Hahm, J. Lincecum, M. Z. Wang, M. H. Maurer, M. Rossner, A. Schneider, A. and M. Schwaninger: Tumor necrosis factorlike weak inducer of apoptosis-induced neurodegeneration. J. Neurosci 24, 8237-8244 (2004) (Pubitemid 39280803)
21. H. Xu, A. Okamoto, J. Ichikawa, T. Ando, K. Tasaka, K. Masuyama, H. Ogawa, H. Yagita, K. Okumura and A. Nakao: TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem. Biophys. Res. Commun 318, 422-427 (2004) (Pubitemid 38553796)
22. S. Campbell, L. C. Burkly, H. X. Gao, J. W. Berman, L. Su, B. Browning, T. Zheng, L. Schiffer, J. S. Michaelson and C. Putterman: Proinflammatory effects of tweak/fn14 interactions in glomerular mesangial cells. J. Immunol 176, 1889-1898 (2006) (Pubitemid 43134334)
23. N. L. Tran, W. S. McDonough, P. J. Donohue, J. A. Winkles, T. J. Berens, K. R. Ross, D. B. Hoelzinger, C. Beaudry, S. W. Coons and M. E. Berens: The human Fn14 receptor gene is upregulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am. J. Pathol 162, 1313-1321 (2003) (Pubitemid 36350675)
24. J. S. Michaelson, S. Cho, B. Browning, T. S. Zheng, J. M. Lincecum, M. Z. Wang, Y. M. Hsu and L. C. Burkly: Tweak induces mammary epithelial branching morphogenesis. Oncogene 24, 2613-2624 (2005) (Pubitemid 40593089)
25. A. Jakubowski, C. Ambrose, M. Parr, J. M. Lincecum, M. Z. Wang, T. S. Zheng, B. Browning, J. S. Michaelson, M. Baetscher, B. Wang, D. M. Bissell and L. C. Burkly: TWEAK induces liver progenitor cell proliferation. J. Clin. Invest 115, 2330-2340 (2005) (Pubitemid 41266195)
26. S. A. Brown, C. M. Richards, H. N. Hanscom, S. L. Feng and J. A. Winkles. The Fn14 cytoplasmic tail binds tumournecrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem. J 371, 395-403 (2003) (Pubitemid 36547622)
27. S. Han, K. Yoon, K. Lee, K. Kim, H. Jang, N. K. Lee, K. Hwang and L. S. Young: TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochem. Biophys. Res. Commun 305, 789-796 (2003) (Pubitemid 36597832)
28. P. J. Donohue, C. M. Richards, S. A. Brown, H. N. Hanscom, J. Buschman, S. Thangada, T. Hla, M. S. Williams and J. A. Winkles: TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler. Thromb. Vasc. Biol 23, 594-600 (2003) (Pubitemid 36438071)
29. L. F. Chen and W. C. Greene: Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol 5, 392-401 (2004)
30. S. Shishodia and B. B. Aggarwal: Nuclear factorkappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat. Res 119, 139-173 (2004)
31. M. P. Mattson and S. Camandola: NF-kappaB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest 107, 247-254 (2001) (Pubitemid 32162153)
32. M. P. Mattson, C. Culmsee, Y. Yu and S. Camandola: Roles of nuclear factor kappaB in neuronal survival and plasticity. J. Neurochem 74, 443-456 (2000) (Pubitemid 30053716)
33. H. L. Pahl: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18, 6853-6866 (1999)
34. R. Polavarapu, M. C. Gongora, J. A. Winkles, and M. Yepes: Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappaB pathway activation. J. Neurosci 25, 10094-10100 (2005) (Pubitemid 41636205)
35. Z. Zheng and M. A. Yenari: Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol. Res 26, 884-892 (2004) (Pubitemid 39628566)
36. Y. Chicheportiche, L. Fossati-Jimack, S. Moll, N. Ibnou-Zekri and S. Izui: Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem. Biophys. Res. Commun 279, 162-165 (2000)
37. S. Campbell, J. Michaelson, L. Burkly and C. Putterman: The role of TWEAK/Fn14 IN the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 9, 2273-2284 (2004)
38. A. M. Mueller, X. Pedre, I. Kleiter, M. Hornberg, A. Steinbrecher and G. Giegerich: Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol 159, 55-65 (2005) (Pubitemid 40126177)
39. M. Nakayama, K. Ishidoh, N. Kayagaki, Y. Kojima, N. Yamaguchi, H. Nakano, E. Kominami, K. Okumura. and H. Yagita: Multiple pathways of TWEAK-induced cell death. J. Immunol 168, 734-743 (2002) (Pubitemid 34049574)
40. M. Nakayama, K. Ishidoh, Y. Kojima, N. Harada, E. Kominami, K. Okumura and H. Yagita: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J. Immunol 170, 341-348 (2003) (Pubitemid 36026158)
41. M. Nakayama, N. Kayagaki, N. Yamaguchi, K. Okumura and H. Yagita: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J. Exp. Med 192, 1373-1380 (200)
42. P. Schneider, R. Schwenzer, E. Haas, F. Muhlenbeck, G. Schubert, P. Scheurich, J. Tschopp and H. Wajant: TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur. J. Immunol 29, 1785-1792 (1999) (Pubitemid 29265533)
43. P. Thorvaldsen, K. Asplund, K. Kuulasmaa, A. M. Rajakangas and M. Schroll: Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke 26, 361-367 (1995)
44. World Health Organization: The World Health Report: 2002: Reducing risks, promoting healthy life. (2002)
45. K. Kariko, D. Weissman and F. A. Welsh: Inhibition of toll-like receptor and cytokine signaling-a unifying theme in ischemic tolerance. J. Cereb. Blood Flow Metab 24:1288-1304 (2004) (Pubitemid 39482492)
46. N. L. Tran, W. S. McDonough, B. A. Savitch, T. F. Sawyer, J. A. Winkles and M. E. Berens: The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J. Biol. Chem 280, 3483-3492 (2005) (Pubitemid 40223813)
47. X. Zhang, J. A. Winkles, M. C. Gongora, R. Polavarapu, J. S. Michaelson, K. Hahm, L. Burkly, M. Friedman, X. J. Li and M. Yepes: TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J. Cereb. Blood Flow Metab. 1-11 (2006)
48. A. Schneider, A. Martin-Villalba, F. Weih, J. Vogel, T. Wirth and M. Schwaninger: NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat. Med 5, 554-559 (1999) (Pubitemid 29220215)
49. L. Xu, Y. Zhan, Y. Wang, G. Z. Feuerstein and X. Wang: Recombinant adenoviral expression of dominant negative IkappaBalpha protects brain from cerebral ischemic injury. Biochem. Biophys. Res. Commun 299, 14-17 (2002) (Pubitemid 35366028)
50. T. C. Polek, M. Talpaz, B. G. Darnay and T. Spivak-Kroizman: TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J. Biol. Chem 278, 32317-32323 (2003) (Pubitemid 37048427)
51. T. Saitoh, M. Nakayama, H. Nakano, H. Yagita, N. Yamamoto and S. Yamaoka: TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J. Biol. Chem 278, 36005-36012 (2003) (Pubitemid 37139919)
52. L. Jin, A. Nakao, M. Nakayama, N. Yamaguchi, Y. Kojima, N. Nakano, R. Tsuboi, K. Okumura, H. Yagita and H. Ogawa: Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J. Invest. Dermatol 122, 1175-1179 (2004) (Pubitemid 38651092)
53. C. N. Lynch, Y. C. Wang, J. K. Lund, Y. W. Chen, J. A. Leal and S. R. Wiley: TWEAK induces angiogenesis and proliferation of endothelial cells. J. Biol. Chem 274, 8455-8459 (1999) (Pubitemid 29164634)
54. N. Harada, M. Nakayama, H. Nakano, Y. Fukuchi, H. Yagita and K. Okumura, K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun 299, 488-493 (2002) (Pubitemid 35365656)
55. G. J. del Zoppo and T. Mabuchi, T: Cerebral microvessel responses to focal ischemia, J. Cereb. Blood Flow Metab 23, 879-894 (2003) (Pubitemid 36959394)
56. P. Rieckmann and B. Engelhardt: Building up the blood-brain barrier. Nat. Med 9, 828-829 (2003) (Pubitemid 36889920)
57. B. T. Hawkins and T. P. Davis: The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev 57:173-185 (2005) (Pubitemid 41043883)
58. L. A. Cunningham, M. Wetzel and G. A. Rosenberg: Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50, 329-339 (2005) (Pubitemid 40780839)
59. A. M. Romanic and J. A. Madri: Extracellular matrixdegrading proteinases in the nervous system. Brain Pathol 4, 145-156 (1994) (Pubitemid 24140502)
60. G. A. Rosenberg, M. Navratil, F. Barone and G. Feuerstein: Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J. Cereb. Blood Flow Metab 16, 360-366 (1996) (Pubitemid 26125324)
61. M. Asahi, K. Asahi, J. C. Jung, G. J. del Zoppo, M. E. Fini and E. H. Lo: Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab 20, 1681-1689 (2000)
62. M. Asahi, X. Wang, T. Mori, T. Sumii, J. C. Jung, M. A., Moskowitz, M. E. Fini and E. H. Lo: Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci 21, 7724-7732 (2001) (Pubitemid 32904971)
63. P. Saas, J. Boucraut, P. R. Walker, A. L. Quiquerez, M. Billot, S. Desplat-Jego, Y. Chicheportiche and P. Y. Dietrich: TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 32, 102-107 (2000)
64. Y. Chicheportiche, R. Chicheportiche, I. Sizing, J. Thompson, C. B. Benjamin, C. Ambrose and J. M. Dayer: Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 4, 126-133 (2002) (Pubitemid 34257346)
65. S. Fukuda, C. A. Fini, T. Mabuchi, J. A. Koziol, L. L. Eggleston and G. J. del Zoppo: Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 35, 998-1004 (2004) (Pubitemid 38419817)
66. Z. Gu, J. Cui, S. Brown, R. Fridman, S. Mobashery, A. Y. Strongin and S. A. Lipton, S. A. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci 25, 6401-6408 (2005) (Pubitemid 40962536)
67. J. F. Kurtzke: Clinical definition for multiple sclerosis treatment trials, Ann. Neurol 36(Suppl), S73-9 (1994) (Pubitemid 24220846)
68. D. A. Hafler:. Multiple sclerosis, J. Clin. Invest 113, 788-794 (2004) (Pubitemid 38544133)
69. C. C. Bernard, T. G. Johns, A. Slavin, M. Ichikawa, C. Ewing, J. Liu and J. Bettadapura: Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J. Mol. Med 75, 77-88 (1997) (Pubitemid 27119487)
70. S. Desplat-Jego, R. Creidy, S. Varriale, N. Allaire, Y. Luo, D. Bernard, D., K. Hahm, L. Burkly and J. Boucraut: Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin. Immunol 117, 15-23 (2005) (Pubitemid 41725465)